<DOC>
	<DOCNO>NCT01452451</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability repeat dos HM11260C give different regimen subject type 2 diabetes mellitus ( T2DM ) stable metformin monotherapy .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study LAPS-Exendin Subjects Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Is male female 18 65 year age , inclusive , screen Has history T2DM stable dose metformin Has HbA1c level screen 7 % 10 % Is pregnant lactating Has type 1 diabetes Has significant change body weight 3 month screen Has fast plasma glucose level great 240 mg/dL ( 13.3 mmol/L ) screening Has estimate glomerular filtration rate rate &lt; 75 mL/min/1.73 m2 ≥75 mL/min/1.73 m2 &lt; estimate glomerular filtration rate &lt; 90 mL/min/1.73 m2 urine albumin urine creatinine ratio &gt; 30 mg/g . Has alanine aminotransferase aspartate aminotransferase value &gt; 2.0 × upper limit normal total bilirubin &gt; 1.5 × upper limit normal unless subject know history Gilbert 's syndrome Has fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) &gt; 250 mg/dL ( &gt; 2.85 mmol/L ) stable lipidlowering therapy least 4 week prior screen , calcitonin ≥50 ng/L . Subjects history Fredrickson 's Type I , IV V hyperlipidemia exclude . Has history GI intolerance , chronic diarrhea , inflammatory bowel disease , partial bypass gastric banding Has acute illness within 5 day first study drug administration Has elevate amylase , ongoing cholelithiasis , cholecystitis screening , history pancreatitis Is heavy tobacco user ( 10 cigarette day ) Is heavy alcohol user Has positive screen drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>